OBJECTIVES: To understand reasons for lost-to-follow-up (LTFU) from a community-based antiretroviral therapy program in Uganda. STUDY DESIGN: Retrospective cohort of patients LTFU between May 31, 2001, to May 31, 2010, was examined. A representative sample of 579 patients traced to ascertain their outcomes. METHODS: Mixed methods were used. Using "stopped care" as the hazard and "self-transferred" as the comparator, we examined using Cox proportional multivariable model risk factors for stopping care. RESULTS: Overall, 2933 of 3954 (74.0%) patients were LTFU. Of 579 of 2933 (19%) patients sampled for tracing, 32 (5.5%) were untraceable, 66(11.4 %) were dead, and 481 (83.0%) found alive. Of those found alive, 232 (40.0%) stopped care, 249 (43.0%) self-transferred, whereas 61 (12.7%) returned to care at Reach Out Mbuya HIV/AIDS Initiative. In adjusted hazards ratios, born-again religion, originating from outside Kampala, resident in Kampala for <5 years but >1 year, having school-age children who were out of school, non-HIV disclosure, CD4 counts >250 cells per cubic millimeter and pre-antiretroviral therapy were associated with increased risk of stopping care. Qualitative interviews revealed return to a normal life as a key reason for LTFU. Of 61 patients who returned to care, their median CD4 count at LTFU was higher than on return into care (401/mm³ vs. 205/mm³, P < 0.0001). CONCLUSIONS: Many patients become LTFU during the course of years, necessitating the need for effective mechanisms to identify those in need of close monitoring. Efforts should be made to improve referrals and mechanisms to track patients who transfer to different facilities. Additionally, tracing of patients who become LTFU is required to convince them to return.
OBJECTIVES: To understand reasons for lost-to-follow-up (LTFU) from a community-based antiretroviral therapy program in Uganda. STUDY DESIGN: Retrospective cohort of patients LTFU between May 31, 2001, to May 31, 2010, was examined. A representative sample of 579 patients traced to ascertain their outcomes. METHODS: Mixed methods were used. Using "stopped care" as the hazard and "self-transferred" as the comparator, we examined using Cox proportional multivariable model risk factors for stopping care. RESULTS: Overall, 2933 of 3954 (74.0%) patients were LTFU. Of 579 of 2933 (19%) patients sampled for tracing, 32 (5.5%) were untraceable, 66(11.4 %) were dead, and 481 (83.0%) found alive. Of those found alive, 232 (40.0%) stopped care, 249 (43.0%) self-transferred, whereas 61 (12.7%) returned to care at Reach Out Mbuya HIV/AIDS Initiative. In adjusted hazards ratios, born-again religion, originating from outside Kampala, resident in Kampala for <5 years but >1 year, having school-age children who were out of school, non-HIV disclosure, CD4 counts >250 cells per cubic millimeter and pre-antiretroviral therapy were associated with increased risk of stopping care. Qualitative interviews revealed return to a normal life as a key reason for LTFU. Of 61 patients who returned to care, their median CD4 count at LTFU was higher than on return into care (401/mm³ vs. 205/mm³, P < 0.0001). CONCLUSIONS: Many patients become LTFU during the course of years, necessitating the need for effective mechanisms to identify those in need of close monitoring. Efforts should be made to improve referrals and mechanisms to track patients who transfer to different facilities. Additionally, tracing of patients who become LTFU is required to convince them to return.
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Samuel A Olowookere; Akinola A Fatiregun; Joshua O Akinyemi; Afolabi E Bamgboye; Gordon K Osagbemi Journal: J Infect Dev Ctries Date: 2008-10-01 Impact factor: 0.968
Authors: Larry W Chang; Stella Alamo; Samuel Guma; Jason Christopher; Tara Suntoke; Richard Omasete; Jennifer P Montis; Thomas C Quinn; Margrethe Juncker; Steven J Reynolds Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: Edwin Masese Machine; Susan L Gillespie; Nuria Homedes; Beatrice J Selwyn; Michael W Ross; Gabriel Anabwani; Gordon Schutze; Mark W Kline Journal: AIDS Care Date: 2016-05-10
Authors: Kathrin Zürcher; Anne Mooser; Nanina Anderegg; Olga Tymejczyk; Margaret J Couvillon; Denis Nash; Matthias Egger Journal: Trop Med Int Health Date: 2017-02-20 Impact factor: 2.622
Authors: Anna Grimsrud; Morna Cornell; Michael Schomaker; Matthew P Fox; Catherine Orrell; Hans Prozesky; Kathryn Stinson; Frank Tanser; Matthias Egger; Landon Myer Journal: J Epidemiol Community Health Date: 2015-12-23 Impact factor: 3.710
Authors: Sarah W Beckham; Chris Beyrer; Peter Luckow; Meg Doherty; Eyerusalem K Negussie; Stefan D Baral Journal: J Int AIDS Soc Date: 2016-11-08 Impact factor: 5.396
Authors: Norma C Ware; Monique A Wyatt; Elvin H Geng; Sylvia F Kaaya; Oche O Agbaji; Winnie R Muyindike; Guerino Chalamilla; Patricia A Agaba Journal: PLoS Med Date: 2013-01-08 Impact factor: 11.069
Authors: Beth Rachlis; Donald C Cole; Monique van Lettow; Michael Escobar; Adamson S Muula; Farah Ahmad; James Orbinski; Adrienne K Chan Journal: PLoS One Date: 2014-07-17 Impact factor: 3.240